Erica Wood
Erica Wood
Also, it looks like the only edge type mapped to `biolink:treats` post refactor is: ``` MONDO:disease_responds_to: operation: invert core_predicate: biolink:treats ``` This source relation does not appear to be in...
That seems fine to me. We are completely transitioned to the RTX-KG2 repository on the KG2 side of things.
I'm going to tag #1447 with this issue regarding data about side effects.
Also, "bioavailability" was mentioned as a priority
"Mechanism of action" is also listed in the notes document as a trait to rank on.
Here is the node in KG2pre: ``` {"category": "biolink:ChemicalEntity", "category_label": "chemical_entity", "creation_date": null, "deprecated": false, "description": "UMLS Semantic Type: STY:T109", "full_name": "related", "has_biological_sequence": null, "id": "CHV:0000018040", "iri": "http://purl.bioontology.org/ontology/CHV/0000018040", "name": "related",...
I'm concerned that some of the removed packages are actually needed. In particular, `bmt` is the Biolink Model Toolkit, which is used for validation purposes. `graphviz` is used by snakemake...
> Where is `bmt` used in the RTX-KG2 project code? I did a search both via GitHub's web browser UI and of the `master` branch code, like this: > >...
New diagram: 
We also will need validation of the slots